Setting a Course for the Future of Tissue EngineeringLeaders in the field were asked what critical steps are needed for tissue engineering to achieve broad critical success by 2021 and the findings were published in the December 2007 issue of Tissue Engineering, published by Mary Ann Liebert, Inc.
A survey of the journal’s editorial board—comprising leaders in the field of tissue engineering from around the globe—yielded a clear picture of the key scientific areas in which researchers need to focus their efforts. Authors Peter Johnson, MD, Co-Editor-in- These findings can help scientists in academia and industry, teachers, and funding agencies plan for the future, design research projects and training programs, and set a course to enable the field of tissue engineering to reach its goals and potential for success in clinical medicine. “Our worldwide editorial board was very helpful in sharing critical opinions regarding the future of tissue engineering. We hope that this offering will prove to be useful to all participants in the field” says Dr. Johnson. Leading the list of strategic initiatives is “angiogenic control,” which defines the ability to provide engineered tissues with an adequate blood supply to nourish their development and survival. Next on the list is “stem cell science,” which encompasses an understanding of stem cell behavior and how to control their growth, development, and function. Also included among the leading strategic goals identified in the survey is “molecular/ Tissue Engineering is an authoritative peer-reviewed journal published monthly in print and online that brings together scientific and medical experts in the fields of biomedical engineering, materials science, molecular and cellular biology, and genetic engineering. Tissue Engineering is the official journal of the Tissue Engineering & Regenerative Medicine International Society (TERMIS). Tables of contents and a free sample issue may be viewed online. Mary Ann Liebert, Inc., is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Human Gene Therapy, Stem Cells and Development, and Cloning and Stem Cells. Its biotechnology trade magazine, Genetic Engineering and Biotechnology News (GEN), was the first in its field and is today the industry’s most widely read publication worldwide. A complete list of the firm’s 60 journals, books, and newsmagazines is available at www.liebertpub.com Mary Ann Liebert, Inc. 140 Huguenot St., New Rochelle, NY 10801 www.liebertpub.com Phone (914) 740-2100 (800) M-LIEBERT Fax (914) 740-2101 Website: www.liebertpub.com End
|
|